Related Experiment Video
Updated: Jul 19, 2026
06:29
Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
Published on: March 1, 2011
Interleukin 6: from bench to bedside.
Norihiro Nishimoto1, Tadamitsu Kishimoto
1Laboratory of Immune Regulation in the Graduate School of Frontier Biosciences, Osaka University, Suita City, Japan. norihiro@fbs.osaka-u.ac.jp
Nature Clinical Practice. Rheumatology
|November 1, 2006
Summary
Interleukin-6 (IL-6) is crucial for immune responses but its dysregulation causes inflammatory and malignant diseases. Targeting IL-6 with therapies like tocilizumab offers effective treatment options for various conditions.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Interleukin-6 (IL-6) is a key cytokine involved in immune regulation, inflammation, and hematopoiesis.
- Dysregulated IL-6 activity is implicated in immune-mediated inflammatory diseases (e.g., rheumatoid arthritis, Crohn's disease) and cancers (e.g., multiple myeloma).
Purpose of the Study:
- To review the multifaceted roles of IL-6 in health and disease.
- To highlight the therapeutic potential of targeting IL-6 signaling pathways.
Main Methods:
- Review of scientific literature on IL-6 biology and clinical applications.
- Discussion of monoclonal antibody development and targeted therapies.
Main Results:
- IL-6's dual role in normal physiology and pathological conditions is elucidated.
- Monoclonal antibodies, such as tocilizumab, targeting the IL-6 receptor demonstrate therapeutic efficacy.
Conclusions:
- Understanding IL-6's pathological roles has paved the way for novel therapeutic strategies.
- Targeting IL-6 provides a successful treatment paradigm for refractory inflammatory and malignant diseases.
